论文部分内容阅读
目的探讨妇科恶性肿瘤患者血小板数量变化特点及其临床意义。方法收集近5年本院妇科恶性肿瘤首诊患者147例(A组)、妇科良性肿瘤患者150例(B组)及健康体检女性150例(C组)治疗前血小板计数进行回顾性分析。根据恶性肿瘤种类,将A组分为卵巢癌组、宫颈癌组、子宫内膜癌组、其他妇科恶性肿瘤组。根据临床期别,又将A组设为A1组(Ⅰ期、Ⅱ期)、A2组(Ⅲ期、Ⅳ期)。结果 (1)A组血小板计数为(268.03±79.977)×109/L,高于B组[(215.38±41.424)×109/L]及C组[(206.40±41.022)×109/L](P<0.05)。A2组血小板计数为(283.13±86.409)×109/L,高于A1组[(254.46±73.101)×109/L](P<0.05)。B组与C组比较,差异无统计学意义(P>0.05)。(2)A组患者中血小板增多的比例为27.9%(41/147),高于B组[4.7%(7/150)]及C组[1.3%(2/150)](P<0.05)。A2组患者中血小板增多的比例为37.7%(20/53),高于A1组[22.3%(21/94)](P<0.05)。B组与C组比较,差异无统计学意义(P>0.05)。(3)卵巢癌组、宫颈癌组、子宫内膜癌组、其他妇科恶性肿瘤组患者血小板增多的比例依次为42.1%(16/38)、25.5%(14/55)、22.2%(8/36)及16.7%(3/18)。结论血小板数量变化与妇科恶性肿瘤发生、发展密切相关。血小板增多可作为评价妇科恶性肿瘤病情进展及预后的一项参考指标。
Objective To investigate the changes of platelet count in patients with gynecologic malignancies and its clinical significance. Methods A total of 147 patients (group A) with gynecologic malignancy diagnosed in our hospital in recent 5 years, 150 patients with benign gynecologic tumor (group B) and 150 healthy women (group C) were retrospectively analyzed. According to the type of malignant tumor, group A was divided into ovarian cancer group, cervical cancer group, endometrial cancer group and other gynecologic malignant tumor group. According to the clinical stage, again in group A as A1 (Ⅰ, Ⅱ), A2 (Ⅲ, Ⅳ). Results The platelet count of group A was (268.03 ± 79.977) × 109 / L, higher than that of group B [(215.38 ± 41.424) × 109 / L] and group C [(206.40 ± 41.022) × 109 / L] <0.05). The platelet count of A2 group was (283.13 ± 86.409) × 109 / L, higher than that of A1 group [(254.46 ± 73.101) × 109 / L] (P <0.05). B group and C group, the difference was not statistically significant (P> 0.05). (2) The proportion of thrombocytopenia in group A was 27.9% (41/147), higher than 4.7% (7/150) in group B and 1.3% (2/150) in group C (P <0.05) . The proportion of thrombocytopenia in group A2 was 37.7% (20/53), which was higher than that in group A1 [22.3% (21/94)] (P <0.05). B group and C group, the difference was not statistically significant (P> 0.05). (3) The proportion of thrombocytopenia in patients with ovarian cancer, cervical cancer, endometrial cancer and other gynecologic malignancies was 42.1% (16/38), 25.5% (14/55) and 22.2% (8 / 36) and 16.7% (3/18). Conclusion The change of platelet count is closely related to the occurrence and development of gynecological malignant tumors. Thrombocytosis can be used as a prognostic evaluation of gynecological malignancy a reference index.